The Maharashtra FDA has revoked the drug sale licenses of Cipla Pharma & Life Sciences' C&F unit in Pune following severe violations in medicine storage and improper labeling of Reactin Plus tablets.
The Maharashtra Food and Drug Administration (FDA) has taken decisive action by cancelling the drug sale licenses of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) unit located in Pune. The decision follows a stringent inspection of the company's main warehouse in Wadki, Pune district, which revealed significant irregularities in the handling and storage of pharmaceutical products.
According to the official statement released on Friday, the cancellation became effective on August 27, 2026. The inspection uncovered alarming lapses, including medicines being stored directly on the warehouse floor rather than on pallets or racks, posing a risk to product integrity. Furthermore, the regulator flagged serious deficiencies in the procedures used to manage and dispose of expired medicines.
Misbranding and Unauthorized Claims
A major component of the violation involved Reactin Plus tablets, a Schedule H prescription medicine. The FDA discovered that the packaging contained unauthorized claims, describing the drug as an "analgesic and antipyretic." Such advertising is strictly prohibited under the Drugs and Cosmetics Act, 1940 and Drugs Rules, 1945. Consequently, the regulator seized stock worth ₹11.19 lakh.
Any violation of rules by any entity involved in the manufacture and distribution of medicines will invite strict action as per law.
Why This Matters: BozokMedia Analysis
BozokMedia analysis shows that this regulatory crackdown highlights a growing intolerance for procedural negligence within the pharmaceutical supply chain. When a major player like Cipla fails to comply with recall directions for misbranded drugs, it undermines public trust in the entire distribution network. This incident serves as a stern warning to all logistics partners that storage standards are non-negotiable.
Historical Background: Regulatory Oversight in India
The pharmaceutical industry in India is governed by a complex framework designed to ensure patient safety. The Drugs and Cosmetics Act regulates everything from the manufacturing process to the final point of sale. 'Schedule H' drugs are particularly scrutinized because they require professional medical supervision, making improper storage or mislabeling a direct threat to public health.
Frequently Asked Questions
1. Why was the Cipla C&F unit's license cancelled?
The license was cancelled due to improper storage (medicines on the floor), discrepancies in stock records, and failure to comply with recall orders for Reactin Plus tablets.
2. What is a Schedule H drug?
Schedule H drugs are prescription-only medicines that can only be sold upon the prescription of a registered medical practitioner.
